Full Library
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Resource type
Journal Article
Authors/contributors
- Maertens, Johan A. (Author)
- Rahav, Galia (Author)
- Lee, Dong-Gun (Author)
- Ponce-de-León, Alfredo (Author)
- Sánchez, Isabel Cristina Ramírez (Author)
- Klimko, Nikolay (Author)
- Sonet, Anne (Author)
- Haider, Shariq (Author)
- Vélez, Juan Diego (Author)
- Raad, Issam (Author)
- Koh, Liang-Piu (Author)
- Karthaus, Meinolf (Author)
- Zhou, Jianying (Author)
- Ben-Ami, Ronen (Author)
- Motyl, Mary R. (Author)
- Han, Seongah (Author)
- Grandhi, Anjana (Author)
- Waskin, Hetty (Author)
Title
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Publication
The Lancet
Date
2021-02-06
Volume
397
Issue
10273
Pages
499-509
Journal Abbr
The Lancet
Accessed
6/6/22, 12:21 PM
ISSN
0140-6736, 1474-547X
Short Title
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis
Language
English
Library Catalog
Extra
Publisher: Elsevier
PMID: 33549194
Citation
Maertens, J. A., Rahav, G., Lee, D.-G., Ponce-de-León, A., Sánchez, I. C. R., Klimko, N., Sonet, A., Haider, S., Vélez, J. D., Raad, I., Koh, L.-P., Karthaus, M., Zhou, J., Ben-Ami, R., Motyl, M. R., Han, S., Grandhi, A., & Waskin, H. (2021). Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. The Lancet, 397(10273), 499–509. https://doi.org/10.1016/S0140-6736(21)00219-1
ORGANISMS
DRUGS AND THERAPIES
Link to this record